ClinicalTrials.gg
RecruitingNCT06711822Updated Dec 2, 2024

The Safety and Performence of ShockPulse-10 in Patients with Coronary Artery Calcification

An interventional study of Shockplus-10 in Coronary Arterial Disease (CAD) and Calcification; Heart, sponsored by Keya Medical. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Keya Medical · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jul 2024, registered Nov 2024).
  • Started Jul 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
205
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .

Read the detailed description

The study will be conducted at 8 sites in China and up to 205 participants will be followed for 180 days post procedure.

Patients ≥18 years of age scheduled for stent procedure with evidence of significant calcified stenosis of left main, or left anterior descending, right coronary artery or left circumflex will be eligible to enroll in the study. The primary endpoint of the study will evaluate procedure success,procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization.

02

Conditions studied

  • Coronary Arterial Disease (CAD)
  • Calcification; Heart

Browse trials for

03

In context

Calcinosis

91 studies on the registry are indexed under Calcinosis; 19 are open to participants now.

This study's planned enrollment of 205 is above the median of 70 across 56 interventional studies indexed under Calcinosis.

Browse Calcinosis studies →

Lead sponsor

Keya Medical is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patient is ≥ 18 years of age;
  2. Patients with significant coronary artery disease (including stable or unstable angina and asymptomatic myocardial ischemia) who are suitable for PCI treatment;
  3. A single newly developed stenosis of the target vessel, which is the left anterior descending artery, right coronary artery, or circumflex artery (or its branches), with stenosis degree ≥70% or ≥50% (Visually inspect ) and accompanied by evidence of ischemia;
  4. The target lesion is a primary, in situ coronary artery lesion;
  5. The reference vessel diameter for the target lesion is 2.0-4.0mm, and the length of the target lesion is ≤40mm (Visually inspect);
  6. Visual assessment indicates that the lesion site can accommodate the passage of a pre-dilator or trial instrument through the lesion;
  7. The target lesion site has moderate to severe calcification (meeting one of the following conditions):

    ① Angiography: Moderate calcification :clearer and more easily visible high-density shadows during cardiac pulsation; Severe calcification :clear high-density shadows both during and at rest;

    ② IVUS calcium score ≥2 points for superficial intimal, deep medial, and mixed calcification;

  8. TIMI grade 3 in target vessel before registration (pre-dilation is allowed);

Key exclusion Criteria:

  1. \< 40%;
  2. class III or IV heart failure;
  3. Patients with single coronary artery supply;
  4. Patients with evidence of dissection at the site of the lesion on imaging;
  5. The imaging suggests that the vascular pathway is tortuous, making it difficult for the pre-dilatation device to reach the target location or to be retrieved;
  6. Patients with active systemic infections;
  7. Patients with uncontrollable severe hypertension (systolic pressure > 180 mmHg or diastolic pressure > 110 mmHg);
  8. Patients with coagulopathy, hypercoagulable state or significant bleeding tendency ( \<10g/dL or count \<80×10\^9/L);
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    Device

    Shockplus-10

    Device: Shockplus-10

Interventions

  • DeviceShockplus-10

    Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians

06

What researchers measure

Primary outcomes

  1. Procedure success

    Procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization

    Time frame: immediately post-procedure or prior to discharge, whichever comes first

  2. Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure

    Freedom from major adverse cardiac events (MACE) within 30(±7days) days of the index procedure;MACE is defined as:Cardiac death; or Myocardial Infarction (MI): or Target Vessel Revascularization

    Time frame: 30(±7days)days post index procedure

07

Study locations

1 of 1 sites recruiting
  • Beijing Anzhen Hosipital
    Beijing, Beijing 010, China
    Recruiting
    • Yanlong REN, Dortor · Contact010-84005400
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06711822
Lead sponsor
Keya Medical
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Jul 1, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Dec 2, 2024

Study contacts

XIANTAO SONG, Dortor
Contact
Song0929@mail.ccmu.edu.cn
010-64412431
XIANTAO SONG, Dortor
principal investigator · Beijing Anzhen Hosipital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion